Table 2 Clinical trials of agents based on TME cells for B-cell lymphoma treatment
From: Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities
TME cells | Target | Agent | Indication | Phase | Identifier |
|---|---|---|---|---|---|
TAMs | SIRPα | TTI-622 | R/R lymphoma R/R multiple myeloma Newly diagnosed acute myeloid leukemia | I | NCT03530683 |
| Â | Â | GS-0189 | R/R NHL | I | NCT04502706 |
| Â | CD47 | Hu5F9-G4 | R/R NHL | I | NCT02953509 |
MDSCs | PI3Kδ/γ | Tenalisib (P65300) | iNHL | II | NCT03711578 |
TANs | SIRPα | IBI188 | Advanced lymphoma | I | NCT03717103 |
| Â | CD47/CD19 | TG-1801 | B-cell lymphoma | I | NCT03804996 |
NK cells | Â | iC9/CAR.19/IL15-transduced CB-NK Cells | B lymphoid malignancies NHL CLL ALL | I/II | NCT03056339 |
| Â | Â | CD19-targeted high-affinity NK | DLBCL | I | NCT04052061 |
| Â | Â | AFM13 | R/R HL | I | NCT01221571 |
| Â | Â | Â | Â | II | NCT02321592 |
| Â | IL-15 | ALT-803 | R/R iNHL | I/II | NCT02384954 |
CAFs | FGFR | JNJ-42756493 | Advanced or refractory lymphoma | I | NCT01962532 |